Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.21.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Recognized Revenues
The Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
  Three Months Ended March 31,
  2021 2020
Seagen $ 366  $ 448 
AstraZeneca 14,500  2,711 
Servier 767  10,102 
Total Revenue $ 15,633  $ 13,261 
Schedule of Potential Milestone Payments
Under the Company’s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions):
  Research, Development, Regulatory & Commercial Milestones Sales Milestones
AstraZeneca $ 1,096  $ 4,275 
Servier 236  211 
Seagen 754  450 
Total potential milestone payments $ 2,086  $ 4,936